A Phase 1 Study of CC-486 as a Single Agent & in Combination With

Clinical Trial Summary

The purpose of the study is to evaluate the safety and to define the Maximal Tolerated Dose (MTD) or the Maximal Administered Dose (MAD) of oral azacitidine as a single agent and in combination with carboplatin (CBDCA) or paclitaxel protein bound particles (ABI-007,ABX) in subjects with relapsed or refractory solid tumors.

See also
Status	Clinical Trial	Phase
Completed	`NCT04879849` - A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers	Phase 1
Completed	`NCT04426825` - A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer	Phase 2
Terminated	`NCT03166631` - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread	Phase 1
Completed	`NCT02810457` - Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer	Phase 3
Completed	`NCT02864394` - Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)	Phase 3
Recruiting	`NCT04592523` - A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
Recruiting	`NCT04838548` - A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT04077463` - A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer	Phase 1
Recruiting	`NCT05167604` - Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
Recruiting	`NCT04603807` - A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases	Phase 3
Completed	`NCT04948411` - Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
Active, not recruiting	`NCT04487080` - A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 3
Not yet recruiting	`NCT04255836` - Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)	Phase 2
Completed	`NCT01953913` - Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation	Phase 3
Recruiting	`NCT05715229` - Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy	Phase 2
Recruiting	`NCT04931654` - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer	Phase 1/Phase 2
Suspended	`NCT05421936` - Osimertinib for NSCLC With Uncommon EGFR Mutations
Completed	`NCT02847377` - A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC	N/A
Completed	`NCT04427072` - Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation	Phase 3
Recruiting	`NCT04823377` - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.	N/A

NCT number	NCT01478685
Study type	Interventional
Source	Celgene
Contact
Status	Completed
Phase	Phase 1
Start date	November 29, 2011
Completion date	November 17, 2015

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms